Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Parkinson's Disease Seven-Market Drug Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.
This report covers the 7 major markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033.
The analyst estimated that the PD market was $3.4 billion across the 7MM in 2023. By the end of the forecast period in 2033, sales across these markets will reach $7.0 billion, increasing at a compound annual growth rate (CAGR) of 7.6%.
The major drivers of growth in the PD market will be the launch of several pipeline products including novel levodopa delivery systems, products targeting non-motor complications and the first ever drugs with disease modifying potential to enter and revolutionize the treatment landscape.
The patent expiry of leading drugs in the market will be the major barrier to market growth.
Scope
- Overview of Parkinson's Disease, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Parkinson's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson's therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson's treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global Parkinson's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson's Disease therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson's Disease therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Key Topics Covered:
1 Parkinson's Disease: Executive Summary
1.1 Summary of Changes
1.2 The PD market will grow to $7.0 billion
1.3 Novel symptomatic treatments will continue to shape the PD market
1.4 Opportunities and challenges for disease-modifying therapies entering the PD market
1.5 What do physicians think?
2 Introduction
2.1 Catalyst
2.2 Related reports
2.3 Upcoming related reports
3 Disease Overview
3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or staging systems
4 Epidemiology
4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of PD
4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of PD by HY clinical staging
4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PD by inheritance type
4.4.6 Forecast assumptions and methods: diagnosed prevalent cases of PD by motor complications
4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of PD by neuropsychiatric complications
4.5 Epidemiological forecast for PD (2023-33)
4.5.1 Diagnosed prevalent cases of PD
4.5.2 Age-specific diagnosed prevalent cases of PD
4.5.3 Sex-specific diagnosed prevalent cases of PD
4.5.4 Diagnosed prevalent cases of PD by HY clinical staging
4.5.5 Diagnosed prevalent cases of PD by type
4.5.6 Diagnosed prevalent cases of PD by inheritance type
4.5.7 Diagnosed prevalent cases of PD by motor complications
4.5.8 Diagnosed prevalent cases of PD by neuropsychiatric complications
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis
5 Disease Management
5.1 Diagnosis and treatment overview
5.2 KOL insights on disease management
6 Current Treatment Options
6.1 Overview
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Effective treatment of motor complications - dyskinesia, off episodes, gait, and balance problems
7.3 New therapies for non-motor complications - psychosis and dementia
7.4 Neuroprotective or disease-modifying agents
7.5 Formulations that reduce pill burden
8 R&D Strategies
8.1 Overview
8.1.1 Development of novel targets ? targeting cell and gene therapies and ?-synuclein
8.1.2 Innovative drug delivery systems
8.1.3 Secondary indications, post marketing requirements, and drug repurposing
8.2 Clinical trials design
8.2.1 Reliable biomarkers of disease progression
8.2.2 Genetic studies required to learn about genetic subtypes of PD
9 Pipeline Assessment
9.1 Overview
9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
10.1 Overview
10.2 Competitive assessment
10.2.1 Levodopa therapies
10.2.2 Dopamine agonists/combinations
10.2.3 Antiparkinsonian agents targeting motor complications
10.2.4 Assets targeting PD dementia
10.2.5 Neuroprotective and disease-modifying agents
11 Current and Future Players
11.1 Overview
11.2 Deal-making trends
12 Market Outlook
12.1 Global markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
13 Appendix
13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.4 Primary research - KOLs interviewed for this report
13.5 Primary research - prescriber survey
Companies Featured
- Merz Pharmaceuticals LLC
- NeuroDerm Ltd
- USB Corp
- Newron
- Italfarmaco SpA
- Kyowa Kirin Co Ltd
- Acadia Pharmaceuticals Inc
- Ono Pharmaceutical Co Ltd
- Sumitomo Pharma Co Ltd
- Otsuka Pharmaceutical Co Ltd
- Novartis AG
- Eisai Co Ltd
- Acorda Therapeutics Inc
- Stada Arzneimittel AG
- Meiji Co Ltd
- Amneal Pharmaceuticals Inc
- Alliance Pharma Plc
- Britannia Pharmaceuticals Ltd
- Annovis Bio Inc
- US WorldMeds LLC
- Hisamitsu Pharmaceutical Co Inc
- Lundbeck LLC
- Viatris
- Supernus Pharmaceuticals Inc
- AbbVie Inc
- Prothena Corp Plc
- Takeda (Pty) Ltd
- Organon
- Pharma Two B Ltd
- Anavex Life Sciences Corp
- Sunovion Pharmaceuticals Asia Pacific Pte Ltd
- Meiji Seika Pharma Co Ltd
- Alkahest Inc
- Teva LLC
- Glaxo Smith Kline (GSK)
- HLS Therapeutics Inc
- Roche
- ADAMAS
- IRLAB Therapeutics AB
- Neuraly Inc
- Taiyo Pharma Co Ltd
- PureIMS BV
- Alora Pharmaceuticals LLC
- PharmaTher Holdings Ltd
For more information about this report visit https://www.researchandmarkets.com/r/n9sypc
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
